; Takeda) as a monotherapy for the treatment of adult patients with metastatic colorectal cancer . The approval is for those who have been previously treated with available standard therapies — including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti–vascular endothelial growth factor agents, and anti–epidermal growth factor receptor agents — and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
Median overall survival was 7.4 months in the treatment group compared with 4.8 months in the placebo group.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Chemo May Benefit Some Older Patients With Metastatic Pancreatic CancerBetter tools are needed to identify vulnerable older patients with metastatic pancreatic cancer who can undergo chemotherapy safely, experts said after finding that some can experience a benefit.
Source: Medscape - 🏆 386. / 55 Read more »
Debulking Does Not Improve Survival in Multiorgan Metastatic CRCInvestigators found that tumor debulking in multiorgan metastatic colorectal cancer will not extend a patient's life.
Source: Medscape - 🏆 386. / 55 Read more »
T-DXd Moves Toward the Front Line for HER2-Low Metastatic BCT-DXd, a targeted drug, extends progression-free survival by 5 months in patients with HER2-low metastatic breast cancer, outperforming chemotherapy as a first-line treatment.
Source: Medscape - 🏆 386. / 55 Read more »
Swimming microrobots deliver cancer-fighting drugs to metastatic lung tumors in miceEngineers at the University of California San Diego have developed microscopic robots, known as microrobots, capable of swimming through the lungs to deliver cancer-fighting medication directly to metastatic tumors.
Source: physorg_com - 🏆 388. / 55 Read more »